Quantcast

Latest Factor VII Stories

2014-06-23 08:27:25

LEVERKUSEN, Germany, June 23, 2014 /PRNewswire/ -- Bayer HealthCare (Bayer) and Dimension Therapeutics, a company focused on developing novel adeno-associated virus (AAV) gene therapy treatments for rare diseases, have entered into a collaboration for the development and commercialization of a novel gene therapy for the treatment of hemophilia A. "Bayer is a worldwide leader in the treatment of hemophilia A and we are highly committed to advancing innovative treatment options for...

2014-06-10 23:02:32

Transparency Market Research added a new report "Hemophilia Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store. Browse the full report: http://www.transparencymarketresearch.com/hemophilia-treatment-market.html. Albany, New York (PRWEB) June 10, 2014 Hemophilia is a group of hereditary genetic disorders that affects the body’s ability to control blood coagulation. The bleeding can be internal or external,...

2014-05-12 08:31:01

- Kogenate® FS antihemophilic factor (recombinant) approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A WHIPPANY, N.J., May 12, 2014 /PRNewswire/ -- Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Bayer's Kogenate® FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults...

2014-05-11 20:21:16

Data showing improved pharmacokinetic profile to be presented at World Federation of Hemophilia Congress MELBOURNE, Australia, May 11, 2014 /PRNewswire/ -- Interim Phase II/III and III findings presented today by CSL Behring at the World Federation of Hemophilia (WFH) 2014 Congress demonstrate an improved pharmacokinetic (PK) profile of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) among hemophilia B patients of all age groups. These...

2014-05-02 08:25:41

KING OF PRUSSIA, Pa., May 2, 2014 /PRNewswire/ -- CSL Behring today announced that the first patient has been enrolled in the pivotal pediatric phase III study to evaluate the efficacy, safety and pharmacokinetics of its novel investigational recombinant factor VIII single chain (rVIII-SingleChain) for the treatment of previously treated children (up to age 11 years) with severe hemophilia A. The study site for this first enrollment is Malaysia. A minimum of 25 previously treated...

2014-04-17 12:30:37

DUBLIN, April 17, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/fclw7g/global_hemophilia) has announced the addition of the "Global Hemophilia Market 2014-2018" [http://www.researchandmarkets.com/research/fclw7g/global_hemophilia ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The analysts forecast the Global Hemophilia market to grow at a CAGR of 6.07 percent over the period...

2014-04-16 16:26:40

LONDON, April 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:PharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_hemophilia_us_drug_forecast_market_analysis_2022.htmlPharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022SummaryThe competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of...

2014-02-18 04:21:07

- The PROTECT VIII study met its primary efficacy and safety objectives for the treatment of patients with hemophilia A WHIPPANY, N.J., Feb. 18, 2014 /PRNewswire/ -- Bayer HealthCare today announced positive results from the PROTECT VIII trial evaluating the company's investigational long-acting site-specific PEGylated recombinant human factor VIII compound BAY 94-9027. The study met its primary objective of protection from bleeds with fewer infusions. In the study, the...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.